PATENT CLAIM ANALYSIS

Application Number: 15924377
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["530", "300000"]

Abstract:
The present disclosure relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present disclosure relates to recurrent gene fusions as clinical targets for cancer.

Claim (Index 8):
The composition of  claim 1 , wherein said NLS is selected from RKKRRQRRR (SEQ ID NO:7), PKKKRKV (SEQ ID NO:5), PAAKRVKLD (SEQ ID NO:6), KRSAEGSNPPKPLKKLR (SEQ ID NO:9), GKKQYKLKH (SEQ ID NO:8), RQARRNRRRRWR (SEQ ID NO:13), KR(K/R), (P/R)XXKRX(K/R) (SEQ ID NO:105), (P/R)XXKR(K/R), d-(K/R)RK, d-(K/R)XRKXX(P/R) (SEQ ID NO:104), d-(K/R)RKXX(P/R) (SEQ ID NO:108), d-VKRKKKP (SEQ ID NO: 14), d-DLKVRKAAP (SEQ ID NO: 15), d-HKLKYQKKG (SEQ ID NO: 16), d-LRKKLPKPPNSGEASRK (SEQ ID NO: 18), d-RRRQRRKKR (SEQ ID NO: 19), or d-RWRRRRNRRAQR (SEQ ID NO:20).

Metadata:
- Claim Count in Document: 44.0
- Percentile: 90.0
- Lexical Diversity: 1.36667
- Patent Class: 530.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13024491', '12272865', '13483142', '12716653', '15149780']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6573744893755387
- 35 USC 102 Novelty (BERT): 0.5349782910255959
- Combined Prediction Score: 0.6451348695405444
- Mean Citation Score: 314.34668800000014
- Max Citation Score: 362.29745
- Similarity Product: 183.99005751197345

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test